Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

A study of circulating anti-CD25 antibodies in non-small cell lung cancer.

Ye L, Li X, Sun S, Guan S, Wang M, Guan X, Lee KH, Wei J, Liu B.

Clin Transl Oncol. 2013 Aug;15(8):633-7. doi: 10.1007/s12094-012-0980-2. Epub 2012 Dec 21.

PMID:
23263913
2.

Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma.

Guan S, Liu B, Zhang C, Lee KH, Sun S, Wei J.

Clin Transl Oncol. 2013 Oct;15(10):825-9. doi: 10.1007/s12094-013-1007-3. Epub 2013 Feb 20.

PMID:
23423807
3.

Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.

Zhang C, Ye L, Guan S, Jin S, Wang W, Sun S, Lee KH, Wei J, Liu B.

Tumour Biol. 2014 Mar;35(3):2047-51.

PMID:
24122232
4.

CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.

Karagöz B, Bilgi O, Gümüs M, Erikçi AA, Sayan O, Türken O, Kandemir EG, Oztürk A, Yaylaci M.

Med Oncol. 2010 Mar;27(1):29-33. doi: 10.1007/s12032-008-9165-9. Epub 2009 Jan 16.

PMID:
19148592
5.

Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?

Liu L, Liu N, Liu B, Yang Y, Zhang Q, Zhang W, Yu P, Jin Y, Guo J, Guan S, Sun S, Miao L, Wei J.

J Cancer Res Clin Oncol. 2012 Oct;138(10):1737-42. Epub 2012 Jun 15.

PMID:
22699933
6.

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH.

Cancer Res. 2001 Jun 15;61(12):4766-72.

7.

Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.

Iizasa T, Fujisawa T, Saitoh Y, Hiroshima K, Ohwada H.

Cancer Immunol Immunother. 1998 Aug;46(6):345-9.

PMID:
9756419
8.

Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.

Pircher A, Gamerith G, Amann A, Reinold S, Popper H, Gächter A, Pall G, Wöll E, Jamnig H, Gastl G, Wolf AM, Hilbe W, Wolf D.

Lung Cancer. 2014 Jul;85(1):81-7. doi: 10.1016/j.lungcan.2014.04.001. Epub 2014 Apr 13.

PMID:
24780112
9.

The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN.

Wang YY, He XY, Cai YY, Wang ZJ, Lu SH.

Target Oncol. 2011 Sep;6(3):147-54. doi: 10.1007/s11523-011-0182-9. Epub 2011 May 25.

PMID:
21611754
10.

Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer.

De Vita F, Turitto G, di Grazia M, Frattolillo A, Catalano G.

Tumori. 1998 Jan-Feb;84(1):33-8.

PMID:
9619711
11.

Study of circulating antibodies against CD25 and FOXP3 in breast cancer.

Liu T, Song YN, Shi QY, Liu Y, Bai XN, Pang D.

Tumour Biol. 2014 Apr;35(4):3779-83. doi: 10.1007/s13277-013-1500-x. Epub 2013 Dec 18.

PMID:
24347486
12.

EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.

Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, Chapman CJ, Allen J, Wood WC, Sewell HF, Robertson JF.

Cancer Prev Res (Phila). 2011 Jul;4(7):1126-34. doi: 10.1158/1940-6207.CAPR-10-0328.

13.

Serum anti-p53 antibodies in patients with lung cancer.

Mack U, Ukena D, Montenarh M, Sybrecht GW.

Oncol Rep. 2000 May-Jun;7(3):669-74.

PMID:
10767388
14.

[Clinical significance of CD4+ CD25+ regulatory T-cells detection in tumor-draining lymph nodes of nonsmall cell lung cancer patients].

Su YJ, Ren K, Li H, Ren XB, Wang CL.

Zhonghua Zhong Liu Za Zhi. 2007 Dec;29(12):922-6. Chinese.

PMID:
18478932
15.

Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer.

Jin Y, Guan S, Liu L, Sun S, Lee KH, Wei J.

Asia Pac J Clin Oncol. 2015 Dec;11(4):e37-41. doi: 10.1111/ajco.12198. Epub 2014 May 9.

PMID:
24811068
16.

Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.

Wang W, Guan S, Sun S, Jin Y, Lee KH, Chen Y, Wei J.

Tumour Biol. 2014 May;35(5):4901-5. doi: 10.1007/s13277-014-1643-4. Epub 2014 Jan 23.

PMID:
24453033
17.

[Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)].

Skrzypski M, Szymanowska A, Janowicz A, Dziadziuszko R, Ramlau R, Kozielski J, Pilarska-Machowicz A, Dobrzańska Z, Bigda J, Krzakowski M, Jassem E, Jassem J.

Pneumonol Alergol Pol. 2002;70(7-8):353-8. Polish.

PMID:
12708076
18.

Clinical usefulness of alpha-crystallin antibodies in non-small cell lung cancer patients.

Cherneva R, Petrov D, Georgiev O, Trifonova N.

Interact Cardiovasc Thorac Surg. 2010 Jan;10(1):14-7. doi: 10.1510/icvts.2009.213546. Epub 2009 Oct 1.

PMID:
19797476
19.

Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.

Pujol JL, Cooper EH, Lehmann M, Purves DA, Dan-Aouta M, Midander J, Godard P, Michel FB.

Br J Cancer. 1993 Jun;67(6):1423-9.

20.

CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.

Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T.

Oncol Rep. 2005 Nov;14(5):1269-73.

PMID:
16211295

Supplemental Content

Support Center